Search Browse Earnings

NewAmsterdam Pharma Co N.V.

Nasdaq:NAMSNasdaq:NAMSW

Pharmaceutical Preparations·NARRDEN, P7

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

NewAmsterdam Pharma Co N.V. — SlamSEC

Revenue

$14.1M

-86.3% YoY

FY 2025

Adj. EBITDA

-$182.9M

-1298.2% margin

FY 2025

Net Income

-$176.9M

-1255.8% margin

FY 2025

EPS (Diluted)

-$2.15

FY 2025

Stock Price

$30.77

+3.0%

2026-03-09

52W Range

$14.06 – $42.00

P/E Ratio

-14.3x

Market Cap

$3.5B

Cash

$340.4M

FY 2025

Total Debt

—

Net Cash

$340.4M

FY 2025

Enterprise Value

$3.2B

Debt / EBITDA

1.9x

FY 2025

EV / EBITDA

-17.5x

Employees

—